Official Title: REN-1654 in Sciatica A Phase 2 Randomized Double-Blind Placebo Controlled Multi-Center Study in Subjects With Pain Due to Lumbosacral Radiculopathy
Status: UNKNOWN
Status Verified Date: 2005-06
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with pain that radiates down the legs and is typical of sciatica lumbosacral radiculopathy These patients will usually have a herniated disc that is causing compression on the nerves coming out of the spinal column
Detailed Description: This is a multi-center randomized double-blind placebo-controlled study to determine the efficacy and tolerability of REN-1654 in subjects with sciatica After screening and baseline clinical assessments subjects will be randomly assigned to receive REN 1654 100 mg or matching placebo once daily for 3 weeks Leg pain back pain and other efficacy measures will be assessed at 1 and 3 weeks after initiation of treatment A subset of patients will undergo analysis of blood levels of REN-1654 during the course of the study pharmacokinetics Subjects will discontinue treatment after 3 weeks and return after a further 3 weeks off therapy for a final clinical assessment 6 weeks after initiation of treatment If a subject does not return for follow-up an effort will be made by telephone to document their clinical status and whether other interventions have been made